Armata Pharmaceuticals Shows Promising Results for AP-SA02 in Severe Staph Infection
Armata's AP-SA02 bacteriophage cocktail showed high cure rates and zero relapse in a Phase 2 trial for complicated Staphylococcus aureus bacteremia (SAB), signaling a potential new standard of care.